What Can and Cannot Be Done Using a Microarray Analysis? Treatment Stratification and Clinical Applications in Oncology

スポンサーリンク

概要

• 論文の詳細を見る

• Ten years have passed since the emergence of microarray technology. Recent microarray procedures have provided reliable results on all platforms and have enabled highly reproducible gene expression measurements. Thus, nearly all technical matters regarding microarray measurements are thought to have been resolved. Treatment stratification for molecular-targeted drugs can now be achieved based on the presence of somatic mutations, gene amplification, and/or protein overexpression. However, no clinically available biomarkers have been identified for molecular-targeted drugs using microarray analysis. Microarray data as a database for the gene expressions of clinical samples may be a critical issue, especially for the development of molecular-targeted treatments. In addition, microarray analysis during early-phase clinical trials for molecular-targeted drugs is considered to provide critical information, including proof-of-concept and confirmation of the inhibition of the target molecule. Meanwhile, OncotypeDX® and MammaPrint® assays have been developed to determine the benefits of chemotherapy for breast cancer patients. These multigene-based assays are commercially available and have shown encouraging results for treatment stratification or decision-making for treatment using cytotoxic drugs in clinical settings. During the development of these assays, numerous samples and efforts were required to create a model using multi-center or inter-group investigations. Based on the success of these models, the development of further assays for determining multigene expressions is likely to increase in the future. In the present article, we introduce our data on mutant epidermal growth factor receptor (EGFR) signaling and amplification of fibroblast growth factor receptor 2 (FGFR2) using microarray analysis, and treatment stratification and clinical applications using gene expression profiles for cancer treatments are discussed.

著者

• Nishio Kazuto

  Department Of Genome Biology Kinki University School Of Medicine

• Arao Tokuzo

  Department Of Genome Biology Kinki University School Of Medicine

• Maegawa Mari

  Department Of Genome Biology Kinki University School Of Medicine

• Matsumoto Kazuko

  Department Of Applied Mathematics Osaka Women's University

• Arao Tokuzo

  Department of Genome Biology, Faculty of Medicine, Kinki University

• Nishio Kazuto

  Department of Genome Biology, Faculty of Medicine, Kinki University

• Matsumoto Kazuko

  Department of Genome Biology, Faculty of Medicine, Kinki University

関連論文

• Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples
• Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU
• Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
• Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells
• A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer
• Highly Sensitive Determination of Plasma Cytokines by Time-Resolved Fluoroimmunoassay; Effect of Bicycle Exercise on Plasma Level of Interleukin-1α (IL-1α), Tumor Necrosis Factorα (TNFα), and Interferonγ (IFNγ)
• Catastrophic Intraabdominal Bleeding Due to Rupture of Pancreaticoduodenal Artery Aneurysm : Successful Transcatheter Arterial Embolization
• The [4+2]Cycloaddition of 2,3-Dimethylbutadiene to the Diselenido Ligand in the Dicationic Dinuclear Ruthenium Complexes
• Analysis of Cisplatin Behavior in a Non-Small Cell Lung Cancer (NSCLC) Cell Line
• Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer
• N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor
• Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III
• Progress in the field of molecular biology and application of biotechnology to medical oncology
• Epidermal growth factor receptor lacking C-terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor
• Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
• Preparation and a Time-Resolved Fluoroimmunoassay Application of New Europium Fluorescent Nanoparticles
• Quantitative Measurement of 17β-Estradiol and Estriol in River Water by Time-Resolved Fluoroimmunoassay
• Quantitative Measurement of p21 Protein in Human Serum by Time-Resolved Fluoroimmunoassay
• Highly Sensitive Detection of Bensulfuron-methyl by Time-Resolved Fluoroimmunoassay Using a Tetradentate β-Diketonate Europium Chelate as a Lebel
• Time-Resolved Fluorometric Deterction of DNA Using a Tetradentate β-Diketonate Europium Chelate as a Label
• Sensitive Time-Resolved Fluoroimmunoassay of Human Thyroid-Stimulating Hormone by Using a New Europium Fluorescent Chelate as a Label
• Fluorescence Enhancement by Electron-Withdrawing Groups on β-Diketones in Eu(III)-β-diketonate-topo Ternary Complexes
• Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition
• Kinetics and Mechanisms of the Axial Ligand Substitution Reaction of the Head-to-head 2-Pyridonato-bridged cis-Diammineplatinum(III) Dinuclear Complex
• Synthesis of S^-and PF_2O_2-Bridged Dinuclear Ruthenium(IV) Complex Obtained from the Reaction of Disulfide-Bridged Ruthenium(III) Dimer Complex with Dioxygen and Water.
• A Novel Diruthenium(II,III) Complex, [{Ru (AN) (TMP)_2}_2 (μ-S_2)-(μ-NH_2NH_2)_2] (CF_3SO_3)_3 ・ Et_2O, with Two Hydrazine Bridges (AN = acetonitrile, TMP = P(OMe)_3)
• Striped dolphin detoxificates mercury as insoluble Hg(S, Se) in the liver
• Graphite-Furnace atomic absorption spectrometry of organomercury and organoselenium in extracts of biological samples with an organopalladium matrix modifier
• Syntheses and characterizations of Mono- and Binuclear Ruthenium(II) Compounds with Mercapto Ligands
• Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell-cycle-associated genes
• Plasma concentrations of VCAM-1 and PAI-1 : A predictive biomarker for post-operative recurrence in colorectal cancer
• Age-Associated Changes in the Open Field Behavior of Male Mice of the ICR/SLC Strain
• The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma
• Highly Sensitive Time-Resolved Fluorometric Determination for Alkylphenols by High Performance Liquid Chromatography Using β-Diketonate Europium Chelate
• Syntheses and Solution Behavior of Antitumor Active Platinum Blue Compounds with Glutarimidate or 3, 3-Dimethylglutarimidate Bridging Ligand
• Epoxidation of Olefins by Water Oxygen Catalyzed by Platinum Blue Complexes
• Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines
• Synthesis of a New Tetradentate β-Diketonate-Europium Chelate That Can Be Covalently Bound to Proteins in Time-Resolved Fluorometry
• Structure and Luminescence Properties of the Tetradentate β-Diketonate-Europium(III) Complexes
• A Novel Binuclear Ruthenium(III) Compound Triply Bridged by Chloride and Disulfide Ligands, [RuC1(OMe)_3}_2(μ-C1)_2(μ-S_2)Ruc1{P(OMe)_3}_2]
• Pseudoconvex domains of general order in Stein manifolds
• Synthesis and Structure of a Disulfido-Bridged Mixed-Valent Ru (II) Ru(III) Complex [{Ru(AN)_3(TMP)_2}_2(μ-S_2)] (PF_6)_3 (AN = acetonitrile, TMP = P(OMe)_3)
• What Can and Cannot Be Done Using a Microarray Analysis? Treatment Stratification and Clinical Applications in Oncology (Target Therapy for Cancer : Anti-cancer Drugs Targeting Growth-Factor Signaling Molecules)
• Synthesis of the First Platinum Blue Complex with 2, 2'-Bipyridine as the Amine Ligand and Its Aqueous Solution Behavior
• Synthesis and Structural Characterization of N, N'-Dialkylimidazolium Tetrachloroplatinate and Monoaquatrichloroplatinate Salts
• Some geometric properties of Levi form of distance to real hypersurfaces in C^2
• 1,4-Dihydroxylation of 1,3-Conjugated Dienes Promoted by the Pt(III) Dinuclear Complex
• An early event of EGFR mutation in pleomorphic carcinoma of the lung
• What Can and Cannot Be Done Using a Microarray Analysis? Treatment Stratification and Clinical Applications in Oncology
• The crystal structure of guanidinium hexamolybdobis(phenylarsonate) tetrahydrate, (CN3H6)4[C6H5As)2Mo6O25H2] 4H2O.
• S3-1 Application of Fluorescent Lanthanide Chelate Compounds in Life Science(THE 46TH ANNUAL MEETING OF THE JAPAN SOCIETY OF HISTOCHEMISTRY AND CYTOCHEMISTRY)
• A study of the inter-elemental effect in the carbon-furnace atomic-absorption spectrometry of selenium and mercury in biological samples by the palladium-addition method.
• Influence of Novel Supramolecular Substance, [2] Rotaxane, on the Caspase Signaling Pathway in Melanoma and Colon Cancer Cells In Vitro
• Boundary distance functions and q-convexity of pseudoconvex domains of general order in Kahler manifolds
• The crystal structure of cis-diammine(orotinato)platinum(II).
• The Crystal Structure of Sodium Molybdate Dihydrate, Na2MoO4·2H2O
• AN EXPLICIT FORMULA FOR THE LEVI FORM OF THE DISTANCE FUNCTION TO REAL HYPERSURFACES IN Cn
• The crystal structure of .ALPHA.-K8SiW11O39 13H2O.

もっと見る 閉じる

スポンサーリンク